Last reviewed · How we verify

Moizerto — Competitive Intelligence Brief

Moizerto (DIFAMILAST) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Immunology.

marketed cAMP-specific 3',5'-cyclic phosphodiesterase 4B Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Moizerto (DIFAMILAST) — OTSUKA PHARMACEUTICAL Co., Ltd.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Moizerto TARGET DIFAMILAST OTSUKA PHARMACEUTICAL Co., Ltd marketed cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Diphyllin diprophylline marketed diprophylline cAMP-specific 3',5'-cyclic phosphodiesterase 4B 1951-01-01
Otezla Otezla L.H. Kircik, M.D. marketed cAMP-specific 3',5'-cyclic phosphodiesterase 4A, cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific 3',5'-cyclic phosphodiesterase 4C

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moizerto — Competitive Intelligence Brief. https://druglandscape.com/ci/difamilast. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: